Loading clinical trials...
Loading clinical trials...
A Randomised, Double-blind, Parallel, Multinational Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 (Proposed Denosumab Biosimilar) vs. Prolia® (EU-sourced) in Postmenopausal Osteoporosis
Conditions
Interventions
MB09 (denosumab biosimilar)
EU-Prolia
+2 more
Locations
64
Bulgaria
AES - DRS - Medical Center Synexus Sofia EOOD
Sofia, Sofia-Grad, Bulgaria
Medical Center Medconsult Pleven OOD
Pleven, Bulgaria
Medical Center Artmed OOD
Plovdiv, Bulgaria
Multiprofile Hospital for Active Treatment Plovdiv
Plovdiv, Bulgaria
Outpatient Clinic for Specialized Medical Help - Medical Center Kuchuk Paris "OOD"
Plovdiv, Bulgaria
Diagnostic and Consulting Center Aleksandrovska EOOD
Sofia, Bulgaria
Start Date
March 16, 2022
Primary Completion Date
December 14, 2023
Completion Date
May 22, 2024
Last Updated
March 21, 2025
NCT07028320
NCT06898060
NCT01631214
Lead Sponsor
mAbxience Research S.L.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions